C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
C12Q 1/683 - Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
2.
ASSESSMENT OF HEMATURIA AND OTHER URINARY TRACT SYMPTOMS
Methods for assessment of subjects with hematuria and/or other suspicious urinary tract symptoms indicative of malignancy are provided, which are particularly useful for detecting primary bladder cancer or alternatively ruling-out bladder cancer (particularly high-grade bladder cancer) in these subjects. The methods provided are based on analysis of DNA methylation markers in DNA from cells of urine samples of the subjects.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
C12Q 1/44 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving esterase
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
Various compositions and methods are disclosed in which a plurality of restriction enzymes, including methylation-sensitive and/or methylation-dependent restriction enzymes, are used for the analysis of cfDNA. Useful combinations can be inactivated by heating to 65° C., ideally for longer than 15 minutes. Restriction digestion of cfDNA can occur for 11 hours or less. Digestion may be followed by amplification and/or sequencing steps.
C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
C12Q 1/34 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase
C12Q 1/48 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving transferase
Provided herein are devices, systems, kits and methods for predicting or determining the gender of a fetus using cell free fetal nucleic acids in a small amount of maternal biological sample. Devices can be used at point of need during early stages of pregnancy and are compatible with communication devices.
Methods for applying machine learning algorithms to nucleic acid sequencing-based diagnostics tests for detection of copy number variation and other genomic abnormalities are described.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G06N 3/044 - Recurrent networks, e.g. Hopfield networks
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
7.
METHODS AND KITS FOR DETERMINING THE EFFICIENCY OF PLASMA SEPARATION FROM WHOLE BLOOD
The present invention provides according to some aspects methods and kits for determining the efficiency of plasma separation from whole blood using quantitative PCR amplification of two amplicons, namely, a short amplicon of e.g. 70-150 bps and a long amplicon of e.g. 350-600 bps. The separation efficiency is determined based on the difference in amplification levels of the two amplicons. Advantageously, the separation efficiency is determined without absolute quantification of DNA and/or determination of copy number of any gene/locus.
Compositions and methods for DNA amplification following a DNA digestion reaction are provided. In particular embodiments, reaction buffers comprising a chelating agent are provided. The provided reaction buffers obviate the need for a dilution and/or a purification step between the DNA digestion and the DNA amplification.
C12Q 1/683 - Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
Methods for the processing and analysis of blood samples obtained with blood collection tubes that reduce contamination of cfDNA by genomic DNA but that inhibit digestion by methylation-sensitive and/or methylation-dependent restriction enzymes.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
C12Q 1/683 - Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
Compositions and methods are provided, for preparing DNA libraries for high- throughput sequencing following methylation-sensitive and/or methylation-dependent enzymatic digestion of the DNA. The provided compositions and methods obviate the need to clean-up the DNA sample between the digestion step and subsequent library preparation steps. The provided compositions and methods are particularly advantageous for library preparation from small amounts of DNA, such as cell-free DNA from body fluid samples.
C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
11.
LOW-COVERAGE, GENOME-WIDE IDENTIFICATION OF MINORITY cfDNA CONTRIBUTORS
In some aspects, the present disclosure provides a method for analyzing cell free DNA (cfDNA). The method can comprise obtaining a biological sample derived from a subject, wherein the biological sample comprises cfDNA. The method can comprise enriching a proportion of cfDNA within the biological sample. The method can comprise sequencing the cfDNA enriched biological sample using low-coverage, genome-wide nucleic acid sequencing. The method can comprise identifying a plurality of minority components present in the sequenced cfDNA enriched biological sample. The method can comprise assigning a designation that represents a low-confidence estimate of minor variant frequency to individual identified minority components present in the sequenced cfDNA enriched biological sample. The method can comprise averaging a plurality of low-confidence estimates of minor variant frequency across a plurality of sequenced genomic loci to produce an estimation of minority component frequency in the cfDNA enriched biological sample.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
12.
MITOCHONDRIAL DNA INTRINSIC CONTROLS FOR USE IN MSRE-DEPENDENT DNA METHYLATION ANALYSIS
The present application provides tools for rapidly, accurately, and accessibly quantifying endonuclease activity. The system is broadly capable of qualifying enzymatic reagents, detecting chemical inhibitors, and optimizing reaction conditions. Minimal adaptations could further enable use in high-throughput screens for enhancers or inhibitors of specific endonucleases. In this context, the present invention demonstrates the utility of mitochondrial DNA (mtDNA) - which is abundant in plasma as cell-free DNA ("cfDNA") and naturally has minimal methylation - as an endogenous digestion control system in MSRE-dependent methylation assays. While demonstrated in the context of qPCR, the control endogenous digestion control systems of the present invention are broadly applicable to MSRE-dependent methylation assays generally, and particularly to those assays that use a multiplex of MSREs having different recognition sequences.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
Methods and systems for personalized cancer management and monitoring are provided, such as evaluating minimal residual disease (MRD), monitoring tumor recurrence, predicting and monitoring response to treatment and prognosis, based on detection and tracking of tumor-associated DNA methylation changes in cell-free DNA samples, particularly cell-free DNA from plasma samples.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G01N 1/22 - Devices for withdrawing samples in the gaseous state
G01N 33/96 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood or serum control standard
Methods and kits for determining the efficiency of plasma separation from whole blood are provided, which use PCR amplification or high-throughput sequencing data of genomic loci that are present at different concentrations in plasma DNA and in whole blood DNA.
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
G01N 33/96 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood or serum control standard
G01N 1/22 - Devices for withdrawing samples in the gaseous state
16.
METHODS AND SYSTEMS FOR DETECTING METHYLATION CHANGES IN DNA SAMPLES
Methods and systems for highly sensitive detection of methylation changes in DNA samples are provided, particularly in DNA samples obtained from biological fluids such as plasma and urine.
In some aspects, the present disclosure provides a method for analyzing cell free DNA (cfDNA). The method can comprise obtaining a biological sample derived from a subject, wherein the biological sample comprises cfDNA. The method can comprise enriching a proportion of cfDNA within the biological sample. The method can comprise sequencing the cfDNA enriched biological sample using low-coverage, genome-wide nucleic acid sequencing. The method can comprise identifying a plurality of minority components present in the sequenced cfDNA enriched biological sample. The method can comprise assigning a designation that represents a low-confidence estimate of minor variant frequency to individual identified minority components present in the sequenced cfDNA enriched biological sample. The method can comprise averaging a plurality of low-confidence estimates of minor variant frequency across a plurality of sequenced genomic loci to produce an estimation of minority component frequency in the cfDNA enriched biological sample.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
The invention provides methods for ultra-deep whole-genome sequencing of human DNA. The methods determine the methylation status of millions of sites in the human genome, wherein said methods use few (if any) DNA amplification cycles.
The invention provides methods, systems and kits for diagnosing lung cancer (and particularly early- stage and/or high-grade lung cancer) in a subject, staging and grading the cancer, evaluating post¬ treatment disease recurrence, monitoring treatment efficacy and providing prognosis, by analysing DNA methylation markers in cell-free DNA from a sample of the subject.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
Methods for evaluating and managing the treatment of non-muscle-invasive bladder cancer (NMIBC) patients are provided, which are particularly useful for adjusting/deciding a treatment plan for these patients. The methods provided are based on analysis of DNA methylation markers in DNA from cells of urine samples of the subjects.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
C12Q 1/683 - Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
C12Q 1/683 - Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
Methods and systems for genetic and epigenetic profiling of DNA samples and detecting genetic and epigenetic changes in DNA samples are provided, which involve digestion of DNA with methylation-sensitive restriction enzymes, followed by high-throughput sequencing and analysis of sequence reads. Advantageously, the methods and systems of the present invention are sensitive yet accurate, and enable working with very low amounts of DNA and receive vast amount of information, including methylation data, mutation data and more, based on sequencing data from a single run.
C12Q 1/683 - Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
Methods and kits for detection of cancer-related mutations in a DNA sample using enzymatic restriction and real-time PCR. A DNA sample is subjected to digestion with a restriction endonuclease to obtain restriction endonuclease-treated DNA, followed by co-amplification of a restriction locus comprising a cancer mutation site and a control locus. A ratio of signal intensities of the amplification products of the restriction locus and the control locus is used to detect the cancer-related mutation.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
C12N 15/66 - General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligationUse of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
24.
ASSESSMENT OF HEMATURIA AND OTHER URINARY TRACT SYMPTOMS
Methods for assessment of subjects with hematuria and/or other suspicious urinary tract symptoms indicative of malignancy are provided, which are particularly useful for detecting primary bladder cancer or alternatively ruling-out bladder cancer (particularly high-grade bladder cancer) in these subjects. The methods provided are based on analysis of DNA methylation markers in DNA from cells of urine samples of the subjects.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
C12Q 1/683 - Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
25.
ASSESSMENT OF HEMATURIA AND OTHER URINARY TRACT SYMPTOMS
C12Q 1/683 - Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
G16H 10/65 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records stored on portable record carriers, e.g. on smartcards, RFID tags or CD
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
in silico/in vitroin silico/in vitro) pipeline for rapid and efficient selection of primer sets for use in multiplex PCR reactions; reagents comprising primer sets for use in multiplex PCR reactions identified by the interlaced pipeline, and PCR reaction systems to amplify a plurality of target DNA templates in a multiplexed fashion using the primer sets identified by the interlaced pipeline.
Methods and systems for assessing the presence of cancer in a subject and predicting the tissue source of the cancer are provided, by analyzing DNA methylation markers in cell- free DNA samples, particularly cell-free DNA from plasma samples.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
C12Q 1/683 - Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
30.
DETECTING METHYLATION CHANGES IN DNA SAMPLES USING RESTRICTION ENZYMES AND HIGH THROUGHPUT SEQUENCING
Methods and systems for genetic and epigenetic profiling of DNA samples and detecting genetic and epigenetic changes in DNA samples are provided, which involve digestion of DNA with methylation-sensitive restriction enzymes, followed by high-throughput sequencing and analysis of sequence reads. Advantageously, the methods and systems of the present invention are sensitive yet accurate, and enable working with very low amounts of DNA and receive vast amount of information, including methylation data, mutation data and more, based on sequencing data from a single run.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
Methods and kits for determining the efficiency of plasma separation from whole blood are provided, using real-time PCR amplification of two amplicons, namely, a short amplicon of e.g. 70-150 bps and a long amplicon of e.g. 350-600 bps. The separation efficiency is determined based on the difference in amplification patterns of the two amplicons.
Various compositions and methods are disclosed in which a plurality of restriction enzymes, including methylation-sensitive and/or methylation-dependent restriction enzymes, are used for the analysis of cfDNA. Useful combinations can be inactivated by heating to 65°C, ideally for longer than 15 minutes. Restriction digestion of cfDNA can occur for 11 hours or less. Digestion may be followed by amplification and/or sequencing steps.
C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
Methods for the processing and analysis of blood samples obtained with blood collection tubes that reduce contamination of cfDNA by genomic DNA but that inhibit digestion by methylation-sensitive and/or methylation-dependent restriction enzymes.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
C12Q 1/683 - Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
Various compositions and methods are disclosed in which a plurality of restriction enzymes, including methylation-sensitive and/or methylation-dependent restriction enzymes, are used for the analysis of cfDNA. Useful combinations can be inactivated by heating to 65°C, ideally for longer than 15 minutes. Restriction digestion of cfDNA can occur for 11 hours or less. Digestion may be followed by amplification and/or sequencing steps.
C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
35.
REACTION BUFFER COMPOSITIONS AND METHODS FOR DNA AMPLIFICATION AND SEQUENCING
Compositions and methods for DNA amplification following a DNA digestion reaction are provided. In particular embodiments, reaction buffers comprising a chelating agent are provided. The provided reaction buffers obviate the need for a dilution and/or a purification step between the DNA digestion and the DNA amplification.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
C12Q 1/683 - Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
Methods and systems for personalized cancer management and monitoring are provided, such as evaluating minimal residual disease (MRD), monitoring tumor recurrence, predicting and monitoring response to treatment and prognosis, based on detection and tracking of tumor-associated DNA methylation changes in cell-free DNA samples, particularly cell-free DNA from plasma samples.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
C12Q 1/6811 - Selection methods for production or design of target specific oligonucleotides or binding molecules
37.
Methods and systems for detecting methylation changes in DNA samples
Methods and systems for highly sensitive detection of methylation changes in DNA samples are provided, particularly in DNA samples obtained from biological fluids such as plasma and urine.
The invention provides methods for ultra-deep whole-genome sequencing of human DNA. The methods determine the methylation status of millions of sites in the human genome, wherein said methods use few (if any) DNA ammplification cycles.
C12Q 1/683 - Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Biochemical reagents for non-medical purposes; diagnostic preparations and reagents for scientific or research use; chemical and diagnostic preparations for clinical or medical laboratory use Diagnostic test kits for medical and clinical use comprised of medical diagnostic reagents for use in identifying and measuring
changes associated with cancer, precancerous conditions, chronic obstructive pulmonary disease (COPD), autoimmune disease
and neurological disease for testing of bodily fluids for use in disease detection, namely, cancer, precancerous conditions, chronic
obstructive pulmonary disease (COPD), autoimmune disease and neurological disease; medical diagnostic assay kits comprised
of medical diagnostic reagents for use in identifying and measuring changes associated with cancer, precancerous conditions,
chronic obstructive pulmonary disease (COPD) autoimmune disease and neurological disease for testing of bodily fluids for use in
disease detection, namely, cancer, precancerous conditions, chronic obstructive pulmonary disease (COPD), autoimmune
disease and neurological disease; medical diagnostic kits comprised of medical diagnostic reagents and assays for testing of
bodily fluids for use in disease detection, namely, cancer, precancerous conditions, chronic obstructive pulmonary disease
(COPD), autoimmune disease and neurological disease in the field of cancer detection or detection, detection of chronic
obstructive pulmonary disease (COPD), autoimmune disease and neurological disease; diagnostic reagents for medical purposes Medical apparatus for medical diagnostic testing in the fields of cancer or chronic obstructive pulmonary disease (COPD),
autoimmune disease and neurological disease Pharmaceutical research and development; consulting services in the field of biotechnology; consulting services in the field of
pharmaceutical research and development; custom design and development of chemical reagents and biochemical assays Consulting services in the field of health; consulting services in the field of diagnostic medical testing; medical analysis for the
diagnosis of cancer and chronic obstructive pulmonary disease (COPD) and autoimmune disease and neurological disease and
prognosis of expected progression of the diseases; medical testing for diagnostic or treatment purposes in the fields of the
detection and treatment of cancer and chronic obstructive pulmonary disease (COPD) and autoimmune disease and neurological
disease; providing cancer screening services; providing medical screening services for chronic obstructive pulmonary disease
(COPD) and autoimmune disease and neurological disease; providing a website featuring information in the fields of the diagnosis
and treatment of cancer and chronic obstructive pulmonary disease (COPD) and autoimmune disease and neurological disease
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Diagnostic test kits for medical and clinical use comprised of medical diagnostic reagents for use in identifying and measuring
changes associated with cancer and precancerous conditions for testing of bodily fluids for use in disease detection, namely,
cancer and precancerous conditions; medical diagnostic assay kits comprised of medical diagnostic reagents for use in identifying
and measuring changes associated with cancer and precancerous conditions for testing of bodily fluids for use in disease
detection, namely, cancer and precancerous conditions; medical diagnostic kits comprised of medical diagnostic Apparatus for medical diagnostic testing in the field of cancer Consulting services in the field of health; consulting services in the field of diagnostic medical testing; medical analysis for the
diagnosis of cancer and prognosis of expected progression of the disease; medical testing for diagnostic or treatment purposes in
the fields of the detection and treatment of cancer; providing medical screening services for cancer diagnosis and treatment of
cancer; providing a website featuring information in the fields of the diagnosis and treatment of cancer
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Diagnostic test kits for medical and clinical use comprised of medical diagnostic reagents for use in identifying and measuring
changes associated with cancer, precancerous conditions, chronic obstructive pulmonary disease (COPD), autoimmune disease
and neurological disease for testing of bodily fluids for use in disease detection, namely, cancer, precancerous conditions, chronic
obstructive pulmonary disease (COPD), autoimmune disease and neurological disease; medical diagnostic assay kits comprised
of medical diagnostic reagents for use in identifying and measuring changes associated with cancer, precancerous conditions,
chronic obstructive pulmonary disease (COPD), autoimmune disease and neurological disease for testing of bodily fluids for use
in disease detection, namely, cancer, precancerous conditions, chronic obstructive pulmonary disease (COPD), autoimmune
disease and neurological disease; medical diagnostic kits comprised of medical diagnostic reagents and assays for testing of
bodily fluids for use in disease detection, namely, cancer, precancerous conditions, chronic obstructive pulmonary disease
(COPD), autoimmune disease and neurological disease in the field of cancer detection, detection of or chronic obstructive
pulmonary disease (COPD), autoimmune disease and neurological disease; diagnostic reagents for medical purposes Medical apparatus for medical diagnostic testing in the fields of cancer and chronic obstructive pulmonary disease (COPD) Consulting services in the field of health; consulting services in the field of diagnostic medical testing; medical analysis for the
diagnosis of cancer and chronic obstructive pulmonary disease (COPD) and autoimmune disease and neurological disease and
prognosis of expected progression of the diseases; medical testing for diagnostic or treatment purposes in the fields of the
detection and treatment of cancer and chronic obstructive pulmonary disease (COPD) and autoimmune disease and neurological
disease; providing cancer screening services; providing medical screening services for chronic obstructive pulmonary disease
(COPD) and autoimmune disease and neurological disease; providing a website featuring information in the fields of the diagnosis
and treatment of cancer and chronic obstructive pulmonary disease (COPD) and autoimmune disease and neurological disease
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Diagnostic test kits for medical and clinical use comprised of medical diagnostic reagents for use in identifying and measuring
changes associated with cancer, precancerous conditions and chronic obstructive pulmonary disease (COPD) for testing of bodily
fluids for use in disease detection, namely, cancer, precancerous conditions and chronic obstructive pulmonary disease (COPD);
medical diagnostic assay kits comprised of medical diagnostic reagents for use in identifying and measuring changes associated
with cancer, precancerous conditions and chronic obstructive pulmonary disease (COPD) for testing of bodily fluids for use in
disease detection, namely, cancer, precancerous conditions and chronic obstructive pulmonary disease (COPD); medical
diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection,
namely, cancer, precancerous conditions and chronic obstructive pulmonary disease (COPD) in the field of cancer detection and
detection of chronic obstructive pulmonary disease (COPD) Medical apparatus for medical diagnostic testing in the fields of cancer and chronic obstructive pulmonary disease (COPD) Consulting services in the field of health; consulting services in the field of diagnostic medical testing; medical analysis for the
diagnosis of cancer and chronic obstructive pulmonary disease (COPD) and prognosis of expected progression of the diseases;
medical testing for diagnostic or treatment purposes in the fields of the detection and treatment of cancer and chronic obstructive
pulmonary disease (COPD); providing cancer screening services; providing medical screening services for chronic obstructive
pulmonary disease (COPD); providing a website featuring information in the fields of the diagnosis and treatment of cancer and
chronic obstructive pulmonary disease (COPD)
43.
DEVICES, SYSTEMS AND METHODS FOR ULTRA-LOW VOLUME LIQUID BIOPSY
Provided herein are devices, systems, kits and methods for obtaining genetic information from cell-free fetal nucleic acids in ultra-low amounts of biological samples. Due to the convenience of obtaining ultra-low amounts of samples, devices, systems, kits and methods can be at least partially employed at a point of need.
Methods and systems for assessing the presence of cancer in a subject and predicting the tissue source of the cancer are provided, by analyzing DNA methylation markers in cell- free DNA samples, particularly cell-free DNA from plasma samples.
C12Q 1/683 - Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G01N 33/49 - Physical analysis of biological material of liquid biological material blood
46.
Methods and systems for detecting methylation changes in DNA samples
Methods and systems for highly sensitive detection of methylation changes in DNA samples are provided, particularly in DNA samples obtained from biological fluids such as plasma and urine.
Described are computer-implemented methods, systems, and platforms for monitoring biological data of a subject, and providing real-time recommendations to the user related to a change in the subjects health status. Disclosed herein are sampling devices in communication with at least one computer processor of the systems and platforms described herein, which sampling devices are configured to measure the level, presence, or absence of a one or more biomarkers indicative of the subjects health status.
G16H 20/00 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
48.
DETECTING METHYLATION CHANGES IN DNA SAMPLES USING RESTRICTION ENZYMES AND HIGH THROUGHPUT SEQUENCING
Methods and systems for genetic and epigenetic profiling of DNA samples and detecting genetic and epigenetic changes in DNA samples are provided, which involve digestion of DNA with methylation-sensitive restriction enzymes, followed by high- throughput sequencing and analysis of sequence reads. Advantageously, the methods and systems of the present invention are sensitive yet accurate, and enable working with very low amounts of DNA and receive vast amount of information, including methylation data, mutation data and more, based on sequencing data from a single run.
C12Q 1/683 - Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
Methods and systems for genetic and epigenetic profiling of DNA samples and detecting genetic and epigenetic changes in DNA samples are provided, which involve digestion of DNA with methylation-sensitive restriction enzymes, followed by high- throughput sequencing and analysis of sequence reads. Advantageously, the methods and systems of the present invention are sensitive yet accurate, and enable working with very low amounts of DNA and receive vast amount of information, including methylation data, mutation data and more, based on sequencing data from a single run.
C12Q 1/683 - Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
Provided herein are devices, systems, kits and methods for obtaining genetic information from cell-free fetal nucleic acids in ultra-low amounts of biological samples. Due to the convenience of obtaining ultra-low amounts of samples, devices, systems, kits and methods can be at least partially employed at a point of need.
Provided herein are devices, systems, kits and methods for obtaining genetic information from cell-free fetal nucleic acids in ultra-low amounts of biological samples. Due to the convenience of obtaining ultra-low amounts of samples, devices, systems, kits and methods can be at least partially employed at a point of need.
Methods and kits for detection of cancer-related mutations in a DNA sample using enzymatic restriction and real-time PCR. A DNA sample is subjected to digestion with a restriction endonuclease to obtain restriction endonuclease-treated DNA, followed by co-amplification of a restriction locus comprising a cancer mutation site and a control locus. A ratio of signal intensities of the amplification products of the restriction locus and the control locus is used to detect the cancer-related mutation.
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
C12N 15/66 - General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligationUse of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
53.
Methods and kits for determining the efficiency of plasma separation from whole blood
Methods and kits for determining the efficiency of plasma separation from whole blood are provided, using real-time PCR amplification of two amplicons, namely, a short amplicon of e.g. 70-150 bps and a long amplicon of e.g. 350-600 bps. The separation efficiency is determined based on the difference in amplification patterns of the two amplicons.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
Methods and systems for highly sensitive detection of methylation changes in DNA samples are provided, particularly in DNA samples obtained from biological fluids such as plasma and urine.
C12Q 1/683 - Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G01N 33/49 - Physical analysis of biological material of liquid biological material blood
56.
METHODS AND SYSTEMS FOR DETECTING METHYLATION CHANGES IN DNA SAMPLES
Methods and systems for highly sensitive detection of methylation changes in DNA samples are provided, particularly in DNA samples obtained from biological fluids such as plasma and urine.
C12Q 1/683 - Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G01N 33/49 - Physical analysis of biological material of liquid biological material blood
42 - Scientific, technological and industrial services, research and design
Goods & Services
Computer security services, namely, computer security threat analysis for protecting data; computer security consultancy in the field of scanning and penetration testing of computers and networks to assess information security vulnerability; development of security systems and contingency planning for information systems; maintenance of computer software relating to computer security and prevention of computer risks
58.
METHODS AND KITS FOR DETERMINING THE EFFICIENCY OF PLASMA SEPARATION FROM WHOLE BLOOD
Methods and kits for determining the efficiency of plasma separation from whole blood are provided, using real-time PCR amplification of two amplicons, namely, a short amplicon of e.g. 70-150 bps and a long amplicon of e.g. 350-600 bps. The separation efficiency is determined based on the difference in amplification patterns of the two amplicons.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Biochemical reagents for non-medical purposes; diagnostic preparations and reagents for scientific or research use; chemical and diagnostic preparations for clinical or medical laboratory use Diagnostic test kits for medical and clinical use comprised of reagents for use in identifying and measuring changes associated with cancer or precancerous conditions; medical diagnostic assay kits comprised of reagents for use in identifying and measuring changes associated with cancer or precancerous conditions; medical diagnostic kits comprised of medical diagnostic reagents and assays for use in the field of cancer detection; diagnostic reagents for medical purposes Apparatus for medical diagnostic testing in the field of cancer Pharmaceutical research and development; consulting services in the fields of biotechnology and pharmaceutical research and development; custom design and development of chemical reagents and biochemical assays Consulting services in the field of health; consulting services in the field of diagnostic medical testing; medical analysis for the diagnosis of cancer and prognosis of expected progression of the disease; medical testing for diagnostic or treatment purposes in the fields of the detection and treatment of cancer; providing cancer screening services; providing a website featuring information in the fields of the diagnosis and treatment of cancer
C12Q 1/683 - Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
Methods are provided for identification of bladder cancer in a subject comprising (a) applying DNA from a urine sample to digestion with a methylation-sensitive restriction endonuclease, (b) co-amplifying from the treated DNA a restriction locus and a control locus, (c) calculating a ratio between signal intensities of the amplification products of the restriction locus and the control locus; and (d) comparing the ratio to one or more reference ratios from healthy or bladder cancer subjects.
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
G06F 19/00 - Digital computing or data processing equipment or methods, specially adapted for specific applications (specially adapted for specific functions G06F 17/00;data processing systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes G06Q;healthcare informatics G16H)
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Diagnostic preparations for clinical or medical laboratories for use in the field of cancer detection Diagnostic test kits for medical and clinical use comprised of markers for use in identifying and measuring changes associated with cancer or precancerous conditions; medical diagnostic assay kits comprised of markers for use in identifying and measuring changes associated with cancer or precancerous conditions; medical diagnostic kits comprised of medical diagnostic markers for use in the field of cancer detection Apparatus for medical diagnostic testing in the field of cancer [ Pharmaceutical research and development; consulting services in the fields of biotechnology and pharmaceutical research and development; custom design and development of chemical reagents and biochemical assays, all in the field of cancer and precancerous conditions ] [ Consulting services in the field of health; consulting services in the field of diagnostic medical testing; ] medical analysis for the diagnosis of cancer and prognosis of expected progression of the disease; medical testing for diagnostic or treatment purposes in the fields of the detection and treatment of cancer; providing cancer screening services; providing a website featuring information in the fields of the diagnosis and treatment of cancer
The present application describes methods for accurate and cost-effective categorization of DNA samples into different types of in vitro generated DNA or different types of natural DNA such as from different tissues and/or physiological/pathologicalstates. The invention achieves categorization by comparing "signal ratios" that are correlated to ratios of methylation levels at specific genomic loci, but does not rely on calculation of actual methylation levels at any genomic locus. Therefore the disclosedinventive method eliminates the requirement for external DNA species and controls, thereby simplifying and increasing the accuracy of the assay. The described inventive technology also enables performing the categorization of DNA together with DNA profiling in the same reaction, thereby allowing for concomitant categorization and determination of identity of the samples.
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
The present invention provides methods for verifying the authenticity of biological samples containing nucleic acid molecules. The methods enable to distinguish between in vitro generated DNA and in vivo generated DNA and can be used in forensics to assure that DNA profiles produced from crime scene samples are genuine. The methods employ an array of nucleic acid based procedures for verifying the authenticity of a DNA sample such as polymerase chain reaction, sodium bisulfite treatment, and methylation-sensitive endonuclease digestion. The invention further provides kits for verifying the authenticity of biological samples containing nucleic acids employing the methods and reagents described in the invention.
